1Chauncey TR.Drug resistance mechanisms in acute leukemia[J].Curr Opin Oncol,2001,13 (1):21-26.
2Biedler J L,Riehm H.Cellular resistance to actinomycin D in Chinesehamster cells in vitro:cross-resistance,radioautographic and cytogenetic studies[J].Cancer Res,1970,30(4):1174-1184.
3Juliano RL,Ling V.A surface glycoprotein modulating drug permeabilityin Chinese hamater ovary cell mutants[J].Biochem Biophys Acta,1976,455 (1):152-162.
5Gurbuxani S,Singh Arya L,Raina V,et al.Significance of MDR1,MRP,GSTpi and GSTmu mRNA expression in acute lymphblastic leukemia in Indian patients[J].Cancer Lett,2001,167 (1):73 -83.
7Maliepaard M,Scheffer GL,Faneyte IF,et al.Subedllular localization and distribution of the breast cancer resistance protein transporter in normal human tissues[J].Cancer Res,2001,61 (8):3458-3464.
8Laredo J,Huynh A,Muller C,et al.Effect of the protein kinase X inhibitor saturosporine on chemosensitivity to claunorubicin of norual and leukemic fresh myeloid cells[J].Blood,1994,84 (1):229 -237.
9del Poeta G,Stasi P,Venditti A,et al.Prognostic value of cell maker analysis in de novo acute myeloid leukemia[J].Leukemia,1994,8(3):388.
10van Der Kolk DM,de Vriew EG,van Putten WL,et al.P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia[J].Clin Cancer Res,2000,6(8):3205-3214.
二级参考文献34
1Steinherz LJ,Steinherz PG,Tan CT, et al. Cardiac toxicity 4 to 20years after completing anthracycline therapy[J]. JAMA, 1991,266(12): 1672 - 1677.
2Shan KA, Lincoff M, Young JB. Anthracycline - induced cardiocytoxicity[J]. Annals of Internal Medicin, 1996,125 (1): 47 - 58.
3Kremer LCM, Vander Pal HJH, Offringa M, et al. Frequency and risk factors of subcliical cardiotoxicity after anthracycline therapy in children: A systematic review[J]. Annals Oncol, 2002, 13:819 -829.
4Bu'Lock FA, Martin RP, Mott MG. Increased risk of cardiac dysfunction after anthracyclines in girls[J]. Med Pediatr Oncol, 1995,24(2): 143 - 144.
5Horenstein MS, Vander Heide RS, L'ecuyer TJ. Molecular basis of anthracycline- induced cardiotoxicity and its prevention [J]. Mol Genet Metab, 2000,71 ( 1 - 2): 436 - 444.
6Giorgio M, Gaetano C, Elena M. Role of iron in anthracycline cardiotoxicity: new tunes for an old song[J]? FASEB J, 1999, 13(2): 199 - 212.
7Swift L, McHowat J, Sarvazyan N. Inhibition of membrane - associated calcium - independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity[J]. Cancer Res, 2003,63(18) :5992- 5998.
8Zhu WD, Zou YZ, Aikawa R, et al. MAPK superfamily plays an important role in daunomycin - induced apoptosis of cardiac myocytes[J]. Circulation,1999,100(20):2100-2107.
9Kim Y, Ma AG, Kitta K, et al. Anthracycline- induced suppression of GATA- 4 transcription factor: implication in the regulation of cardiac myocyte apoptosis[J]. Mol Pharmacol, 2003,63 (2): 368 -377.
10Safra T. Cardiac safety of liposomal anthracyclines[J]. Oncologist,2003,8 (suppl 2): S17 - S24.
